Guggenheim Initiates Coverage On Cullinan Therapeutics with Buy Rating, Announces Price Target of $30
Benzinga Newsdesk 9 months ago
NewsPrice TargetInitiationAnalyst Ratings
Guggenheim analyst Brad Canino initiates coverage on Cullinan Therapeutics (NASDAQ:CGEM) with a Buy rating and announces Price Target of $30.
Guggenheim analyst Brad Canino initiates coverage on Cullinan Therapeutics (NASDAQ:CGEM) with a Buy rating and announces Price Target of $30.